# OnCo record azalea-therapeutics (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/azalea-therapeutics/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "azalea-therapeutics" ;
  schema:name "Azalea Therapeutics"@en ;
  schema:description "Azalea Therapeutics is trying to turn a patient's own T cells into cancer-fighting CAR-T cells inside the body, with an infusion, instead of collecting the cells and engineering them in a laboratory. Its first medicines, aimed at B-cell blood cancers and myeloma, had not reached human trials when it launched in 2025."@en ;
  schema:url <https://onco.cc/companies/azalea-therapeutics/>, <https://azaleatx.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://azaleatx.com/>, <https://www.biospace.com/press-releases/azalea-therapeutics-launches-with-82-million-financing-to-redefine-precision-genomic-medicines-by-engineering-cells-directly-inside-each-patient> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:sections <https://onco.cc/fronts/cell-therapy/>, <https://onco.cc/fronts/immunotherapy/> ;
  onco:technologies <https://onco.cc/technologies/in-vivo-car-t/>, <https://onco.cc/technologies/in-vivo-gene-editing-cancer/> ;
  onco:targets <https://onco.cc/targets/cd19/>, <https://onco.cc/targets/bcma/> .